Bristol Myers Squibb advanced mezigdomide in multiple myeloma with Phase 3 data showing a delayed progression-or-death outcome versus carfilzomib and dexamethasone alone in the SUCCESSOR-2 trial. In the study, mezigdomide plus standard agents reduced the risk of progression or death by 52% and pushed median progression-free survival to roughly 18 months versus about 8.3 months for the comparator. The company also reported higher response rates and more frequent undetectable disease status in the mezigdomide arm, while noting increased severe adverse events with the combination. The readout strengthens BMS’ push to position CELMoDs—cereblon E3 ligase modulator drugs—as potential successors to its older immunomodulatory backbone in a crowded myeloma pipeline increasingly shaped by bispecifics and cell therapies. With the first Phase 3 mezigdomide milestone landing at ASCO, attention will shift to confirmatory plans, safety management, and sequencing relative to emerging relapse regimens.